Ellen Burnham
Concepts (549)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 38 | 2025 | 817 | 6.580 |
Why?
| | Bronchoalveolar Lavage Fluid | 22 | 2022 | 649 | 1.970 |
Why?
| | Respiratory Insufficiency | 10 | 2025 | 326 | 1.930 |
Why?
| | Lung | 19 | 2025 | 4106 | 1.750 |
Why?
| | Alcohol-Related Disorders | 7 | 2015 | 125 | 1.660 |
Why?
| | Cannabis | 5 | 2025 | 500 | 1.320 |
Why?
| | Pneumonia | 9 | 2023 | 644 | 1.310 |
Why?
| | Intensive Care Units | 20 | 2025 | 853 | 1.310 |
Why?
| | Ethanol | 11 | 2022 | 614 | 1.290 |
Why?
| | Acute Lung Injury | 10 | 2022 | 299 | 1.270 |
Why?
| | Respiratory Mucosa | 4 | 2020 | 322 | 1.240 |
Why?
| | Critical Illness | 21 | 2024 | 831 | 1.180 |
Why?
| | Marijuana Smoking | 3 | 2025 | 261 | 1.100 |
Why?
| | Sepsis | 6 | 2020 | 610 | 1.080 |
Why?
| | Gene Expression | 3 | 2020 | 1488 | 1.030 |
Why?
| | Macrophages, Alveolar | 9 | 2021 | 396 | 1.010 |
Why?
| | Cytokines | 9 | 2025 | 2080 | 0.960 |
Why?
| | Critical Care | 10 | 2021 | 640 | 0.960 |
Why?
| | Survivors | 8 | 2025 | 498 | 0.910 |
Why?
| | Middle Aged | 72 | 2025 | 33604 | 0.900 |
Why?
| | Inflammation Mediators | 4 | 2016 | 513 | 0.880 |
Why?
| | Central Nervous System Depressants | 2 | 2021 | 86 | 0.840 |
Why?
| | Pulmonary Alveoli | 6 | 2016 | 408 | 0.830 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 56 | 0.830 |
Why?
| | Acetates | 2 | 2021 | 79 | 0.830 |
Why?
| | Stem Cells | 5 | 2015 | 599 | 0.800 |
Why?
| | Streptococcus pneumoniae | 2 | 2018 | 169 | 0.800 |
Why?
| | Adult | 66 | 2025 | 38201 | 0.800 |
Why?
| | Pulmonary Fibrosis | 3 | 2022 | 399 | 0.780 |
Why?
| | Hospital Mortality | 7 | 2025 | 918 | 0.780 |
Why?
| | Humans | 130 | 2025 | 138651 | 0.770 |
Why?
| | Mentors | 4 | 2014 | 209 | 0.770 |
Why?
| | Substance Withdrawal Syndrome | 4 | 2021 | 184 | 0.760 |
Why?
| | Leukocytes, Mononuclear | 3 | 2017 | 571 | 0.750 |
Why?
| | Smoking | 8 | 2021 | 1591 | 0.750 |
Why?
| | Lung Diseases | 3 | 2021 | 785 | 0.750 |
Why?
| | Cerebrovascular Circulation | 2 | 2021 | 269 | 0.710 |
Why?
| | Male | 80 | 2025 | 68260 | 0.690 |
Why?
| | Female | 82 | 2025 | 73763 | 0.690 |
Why?
| | Hospitalization | 9 | 2023 | 2235 | 0.680 |
Why?
| | Behavior | 1 | 2021 | 92 | 0.670 |
Why?
| | Thalamus | 2 | 2021 | 117 | 0.660 |
Why?
| | Hypnotics and Sedatives | 4 | 2025 | 211 | 0.660 |
Why?
| | Respiration, Artificial | 13 | 2025 | 670 | 0.660 |
Why?
| | Glycerophospholipids | 4 | 2024 | 34 | 0.660 |
Why?
| | Case-Control Studies | 14 | 2022 | 3523 | 0.660 |
Why?
| | Burnout, Professional | 4 | 2022 | 448 | 0.640 |
Why?
| | Hallucinogens | 1 | 2021 | 110 | 0.610 |
Why?
| | Cigarette Smoking | 2 | 2020 | 102 | 0.600 |
Why?
| | RNA, Messenger | 5 | 2020 | 2815 | 0.580 |
Why?
| | Glutathione | 5 | 2016 | 355 | 0.580 |
Why?
| | Antioxidants | 4 | 2016 | 593 | 0.570 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2018 | 47 | 0.560 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 544 | 0.560 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 279 | 0.560 |
Why?
| | Toll-Like Receptor 2 | 2 | 2016 | 117 | 0.550 |
Why?
| | Epithelial Cells | 4 | 2021 | 1102 | 0.550 |
Why?
| | Inflammation | 8 | 2025 | 2850 | 0.550 |
Why?
| | Xanthine Dehydrogenase | 1 | 2017 | 25 | 0.540 |
Why?
| | Tobacco Products | 1 | 2019 | 129 | 0.540 |
Why?
| | Physicians, Women | 1 | 2019 | 87 | 0.540 |
Why?
| | Bronchoalveolar Lavage | 7 | 2023 | 92 | 0.530 |
Why?
| | Biomedical Research | 2 | 2021 | 694 | 0.510 |
Why?
| | Toll-Like Receptor 4 | 2 | 2016 | 275 | 0.500 |
Why?
| | Blood-Air Barrier | 2 | 2008 | 12 | 0.490 |
Why?
| | Organ Dysfunction Scores | 1 | 2016 | 49 | 0.490 |
Why?
| | Alcohol Drinking | 6 | 2025 | 808 | 0.480 |
Why?
| | Marijuana Abuse | 1 | 2018 | 226 | 0.480 |
Why?
| | Burns | 4 | 2024 | 341 | 0.470 |
Why?
| | Azithromycin | 1 | 2015 | 97 | 0.450 |
Why?
| | Tomography | 2 | 2025 | 43 | 0.440 |
Why?
| | Electric Impedance | 2 | 2025 | 111 | 0.440 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 1045 | 0.420 |
Why?
| | Professional Autonomy | 1 | 2013 | 30 | 0.420 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 172 | 0.410 |
Why?
| | Aged | 33 | 2025 | 24024 | 0.410 |
Why?
| | Research Support as Topic | 2 | 2011 | 117 | 0.410 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2698 | 0.400 |
Why?
| | Cells, Cultured | 8 | 2018 | 4181 | 0.400 |
Why?
| | Lipopolysaccharides | 5 | 2017 | 888 | 0.400 |
Why?
| | Bronchoscopy | 3 | 2023 | 225 | 0.390 |
Why?
| | Oxidative Stress | 5 | 2017 | 1316 | 0.390 |
Why?
| | Retrospective Studies | 23 | 2025 | 15909 | 0.390 |
Why?
| | Immunity, Innate | 1 | 2018 | 824 | 0.390 |
Why?
| | Drugs, Chinese Herbal | 1 | 2012 | 21 | 0.370 |
Why?
| | Asthma | 2 | 2022 | 1888 | 0.370 |
Why?
| | Academic Medical Centers | 2 | 2014 | 514 | 0.360 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2013 | 262 | 0.350 |
Why?
| | Imaging, Three-Dimensional | 2 | 2025 | 564 | 0.340 |
Why?
| | Biomarkers | 14 | 2024 | 4092 | 0.340 |
Why?
| | Venous Thromboembolism | 3 | 2020 | 324 | 0.340 |
Why?
| | Gene Expression Regulation | 6 | 2022 | 2590 | 0.330 |
Why?
| | Personnel Selection | 1 | 2011 | 79 | 0.320 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2009 | 11 | 0.320 |
Why?
| | Malondialdehyde | 2 | 2021 | 29 | 0.320 |
Why?
| | Acetaldehyde | 2 | 2021 | 17 | 0.320 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2010 | 94 | 0.310 |
Why?
| | Muscular Diseases | 3 | 2017 | 112 | 0.310 |
Why?
| | Medical Staff, Hospital | 1 | 2010 | 82 | 0.310 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1818 | 0.310 |
Why?
| | Pneumococcal Infections | 1 | 2010 | 110 | 0.300 |
Why?
| | Cohort Studies | 13 | 2020 | 5697 | 0.300 |
Why?
| | Multiple Organ Failure | 3 | 2006 | 126 | 0.290 |
Why?
| | Smokers | 2 | 2021 | 144 | 0.290 |
Why?
| | Hypoxia | 3 | 2025 | 1149 | 0.280 |
Why?
| | Epidemics | 2 | 2019 | 91 | 0.280 |
Why?
| | Burns, Inhalation | 2 | 2017 | 9 | 0.270 |
Why?
| | Pulmonary Embolism | 3 | 2019 | 235 | 0.270 |
Why?
| | Airway Extubation | 3 | 2013 | 59 | 0.270 |
Why?
| | Sexism | 2 | 2019 | 67 | 0.270 |
Why?
| | Betacoronavirus | 2 | 2020 | 272 | 0.270 |
Why?
| | Benzodiazepines | 2 | 2025 | 154 | 0.260 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2006 | 6 | 0.260 |
Why?
| | Endothelial Cells | 4 | 2011 | 791 | 0.260 |
Why?
| | Pilot Projects | 6 | 2025 | 1765 | 0.260 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 189 | 0.260 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1244 | 0.260 |
Why?
| | Multivariate Analysis | 5 | 2023 | 1482 | 0.260 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 229 | 0.260 |
Why?
| | Deglutition Disorders | 3 | 2013 | 148 | 0.250 |
Why?
| | Fibronectins | 1 | 2007 | 131 | 0.250 |
Why?
| | Young Adult | 13 | 2024 | 13305 | 0.250 |
Why?
| | APACHE | 4 | 2013 | 64 | 0.250 |
Why?
| | Marijuana Use | 2 | 2022 | 206 | 0.250 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2017 | 155 | 0.240 |
Why?
| | Risk Factors | 16 | 2020 | 10252 | 0.240 |
Why?
| | Preoperative Care | 1 | 2008 | 367 | 0.240 |
Why?
| | Administration, Inhalation | 3 | 2025 | 595 | 0.240 |
Why?
| | Anesthesiology | 1 | 2008 | 159 | 0.240 |
Why?
| | Immunity, Cellular | 2 | 2018 | 269 | 0.240 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1157 | 0.240 |
Why?
| | Pediatrics | 1 | 2013 | 1078 | 0.240 |
Why?
| | United States | 16 | 2025 | 14938 | 0.230 |
Why?
| | Polyunsaturated Alkamides | 1 | 2025 | 10 | 0.230 |
Why?
| | Tobacco Use Cessation | 1 | 2025 | 26 | 0.230 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2005 | 54 | 0.230 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 370 | 0.230 |
Why?
| | Arachidonic Acids | 1 | 2025 | 63 | 0.230 |
Why?
| | Coronavirus Infections | 2 | 2020 | 367 | 0.230 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 44 | 0.230 |
Why?
| | Flow Cytometry | 2 | 2024 | 1192 | 0.220 |
Why?
| | Propofol | 1 | 2025 | 88 | 0.220 |
Why?
| | Endocannabinoids | 1 | 2025 | 64 | 0.220 |
Why?
| | Dysbiosis | 2 | 2024 | 178 | 0.220 |
Why?
| | Immunity | 1 | 2025 | 140 | 0.220 |
Why?
| | Bacterial Proteins | 1 | 2010 | 892 | 0.210 |
Why?
| | E-Selectin | 1 | 2004 | 56 | 0.210 |
Why?
| | Patient Acceptance of Health Care | 3 | 2019 | 858 | 0.210 |
Why?
| | Quality of Life | 2 | 2013 | 2954 | 0.210 |
Why?
| | Patient Discharge | 3 | 2024 | 916 | 0.210 |
Why?
| | Anticoagulants | 2 | 2019 | 667 | 0.210 |
Why?
| | Aged, 80 and over | 10 | 2022 | 7677 | 0.210 |
Why?
| | Patient Admission | 1 | 2025 | 202 | 0.200 |
Why?
| | Interleukin-1beta | 2 | 2017 | 378 | 0.200 |
Why?
| | Immunophenotyping | 1 | 2024 | 327 | 0.200 |
Why?
| | Internship and Residency | 1 | 2013 | 1187 | 0.200 |
Why?
| | Shock, Septic | 2 | 2022 | 210 | 0.200 |
Why?
| | Lung Injury | 2 | 2016 | 224 | 0.190 |
Why?
| | Dyspnea | 2 | 2019 | 255 | 0.190 |
Why?
| | Interferons | 2 | 2016 | 195 | 0.190 |
Why?
| | Polyneuropathies | 2 | 2017 | 57 | 0.190 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2022 | 23 | 0.190 |
Why?
| | Epithelium | 2 | 2021 | 316 | 0.180 |
Why?
| | Smoke Inhalation Injury | 2 | 2012 | 30 | 0.180 |
Why?
| | Age Factors | 4 | 2021 | 3256 | 0.180 |
Why?
| | Fibroblasts | 3 | 2013 | 1003 | 0.180 |
Why?
| | Smoking Cessation | 1 | 2025 | 436 | 0.180 |
Why?
| | Double-Blind Method | 4 | 2014 | 1949 | 0.180 |
Why?
| | Delirium | 1 | 2023 | 93 | 0.180 |
Why?
| | Interleukin-8 | 3 | 2018 | 271 | 0.180 |
Why?
| | Alcohol Abstinence | 1 | 2021 | 13 | 0.180 |
Why?
| | Societies, Medical | 2 | 2025 | 839 | 0.180 |
Why?
| | Cell Count | 2 | 2015 | 325 | 0.170 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.170 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.170 |
Why?
| | Feces | 1 | 2024 | 486 | 0.170 |
Why?
| | Neutrophils | 3 | 2017 | 1274 | 0.170 |
Why?
| | Physicians | 3 | 2022 | 932 | 0.160 |
Why?
| | Pandemics | 4 | 2022 | 1641 | 0.160 |
Why?
| | Random Allocation | 1 | 2021 | 363 | 0.160 |
Why?
| | Animals | 18 | 2025 | 37217 | 0.160 |
Why?
| | Phagocytosis | 2 | 2014 | 387 | 0.160 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2018 | 346 | 0.160 |
Why?
| | Comorbidity | 4 | 2020 | 1656 | 0.160 |
Why?
| | Permeability | 2 | 2012 | 161 | 0.160 |
Why?
| | Immunoglobulin A | 1 | 2021 | 214 | 0.160 |
Why?
| | Capacity Building | 1 | 2020 | 62 | 0.160 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1089 | 0.160 |
Why?
| | Career Choice | 2 | 2012 | 229 | 0.160 |
Why?
| | Chemokines | 2 | 2018 | 226 | 0.160 |
Why?
| | Cardiology | 1 | 2022 | 279 | 0.150 |
Why?
| | von Willebrand Factor | 1 | 2019 | 81 | 0.150 |
Why?
| | Homeostasis | 1 | 2003 | 614 | 0.150 |
Why?
| | Prevalence | 3 | 2025 | 2727 | 0.150 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Disaster Planning | 1 | 2020 | 97 | 0.150 |
Why?
| | Wounds and Injuries | 1 | 2006 | 833 | 0.150 |
Why?
| | Needs Assessment | 1 | 2021 | 379 | 0.150 |
Why?
| | Faculty, Medical | 1 | 2022 | 290 | 0.150 |
Why?
| | Pyridines | 2 | 2010 | 494 | 0.150 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 935 | 0.150 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 36 | 0.150 |
Why?
| | Macrolides | 1 | 2019 | 67 | 0.150 |
Why?
| | Brain | 3 | 2021 | 2792 | 0.150 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 335 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 7 | 0.140 |
Why?
| | Statistics, Nonparametric | 4 | 2014 | 433 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Length of Stay | 4 | 2020 | 1238 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 23 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 25 | 0.140 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 25 | 0.140 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 173 | 0.140 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 84 | 0.140 |
Why?
| | Cardiologists | 1 | 2018 | 45 | 0.140 |
Why?
| | Decision Making | 1 | 2025 | 948 | 0.140 |
Why?
| | Apoptosis | 3 | 2014 | 2546 | 0.140 |
Why?
| | Pyrazoles | 1 | 2001 | 425 | 0.130 |
Why?
| | Hospitals, University | 2 | 2015 | 175 | 0.130 |
Why?
| | Occupational Therapy | 1 | 2019 | 99 | 0.130 |
Why?
| | Chemokine CCL2 | 1 | 2017 | 116 | 0.130 |
Why?
| | Heparin | 1 | 2019 | 258 | 0.130 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 170 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2001 | 966 | 0.130 |
Why?
| | Tobacco Use | 1 | 2017 | 65 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 984 | 0.130 |
Why?
| | Transforming Growth Factor beta | 3 | 2022 | 488 | 0.130 |
Why?
| | Cystine | 1 | 2016 | 17 | 0.130 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 176 | 0.130 |
Why?
| | Interleukin-10 | 1 | 2018 | 304 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 549 | 0.130 |
Why?
| | Treatment Outcome | 9 | 2022 | 10923 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1323 | 0.120 |
Why?
| | Interleukin-6 | 2 | 2018 | 785 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2021 | 4315 | 0.120 |
Why?
| | Substance-Related Disorders | 1 | 2025 | 1086 | 0.120 |
Why?
| | Disulfides | 1 | 2016 | 97 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 696 | 0.120 |
Why?
| | Teichoic Acids | 1 | 2016 | 14 | 0.120 |
Why?
| | Hospitalists | 1 | 2020 | 247 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2014 | 5112 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2001 | 849 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 335 | 0.120 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 308 | 0.120 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 280 | 0.120 |
Why?
| | RNA Splicing | 1 | 2017 | 270 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 181 | 0.120 |
Why?
| | Proteins | 2 | 2021 | 1006 | 0.120 |
Why?
| | Inflammasomes | 1 | 2017 | 133 | 0.120 |
Why?
| | Patient Selection | 2 | 2023 | 676 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2017 | 227 | 0.120 |
Why?
| | Hospitals | 1 | 2020 | 695 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 101 | 0.120 |
Why?
| | Cysteine | 1 | 2016 | 203 | 0.120 |
Why?
| | Urinary Bladder | 1 | 2017 | 187 | 0.110 |
Why?
| | Cannabinoids | 1 | 2017 | 168 | 0.110 |
Why?
| | Acetylcysteine | 1 | 2016 | 142 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 657 | 0.110 |
Why?
| | Cholesterol | 1 | 2017 | 403 | 0.110 |
Why?
| | Signal Transduction | 3 | 2022 | 5086 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2017 | 290 | 0.110 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2012 | 150 | 0.110 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 1076 | 0.110 |
Why?
| | Severity of Illness Index | 5 | 2016 | 2851 | 0.110 |
Why?
| | Transcriptome | 1 | 2020 | 967 | 0.110 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 68 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1235 | 0.100 |
Why?
| | Third-Party Consent | 1 | 2013 | 20 | 0.100 |
Why?
| | Competency-Based Education | 1 | 2014 | 70 | 0.100 |
Why?
| | Professional Competence | 1 | 2014 | 97 | 0.100 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 43 | 0.100 |
Why?
| | Total Lung Capacity | 1 | 2013 | 32 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 415 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3307 | 0.100 |
Why?
| | Aging | 2 | 2017 | 1855 | 0.100 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2013 | 40 | 0.100 |
Why?
| | Disease Progression | 1 | 2020 | 2749 | 0.100 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 78 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1213 | 0.100 |
Why?
| | Financial Support | 1 | 2012 | 22 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2017 | 401 | 0.100 |
Why?
| | Logistic Models | 5 | 2017 | 2065 | 0.100 |
Why?
| | Speech-Language Pathology | 1 | 2012 | 23 | 0.100 |
Why?
| | Interleukin-12 | 1 | 2013 | 123 | 0.100 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1470 | 0.090 |
Why?
| | Cell Survival | 1 | 2015 | 1123 | 0.090 |
Why?
| | Informed Consent | 1 | 2013 | 188 | 0.090 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 63 | 0.090 |
Why?
| | Neuregulin-1 | 1 | 2012 | 46 | 0.090 |
Why?
| | Acute Disease | 2 | 2025 | 994 | 0.090 |
Why?
| | Vital Capacity | 1 | 2013 | 312 | 0.090 |
Why?
| | Pepsin A | 1 | 2011 | 19 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3637 | 0.090 |
Why?
| | Ubiquitin | 1 | 2012 | 72 | 0.090 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 83 | 0.090 |
Why?
| | Serotonin | 1 | 2014 | 322 | 0.090 |
Why?
| | Lipid Peroxidation | 1 | 2012 | 151 | 0.090 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 31 | 0.090 |
Why?
| | Phytotherapy | 1 | 2012 | 81 | 0.090 |
Why?
| | Prospective Studies | 6 | 2021 | 7554 | 0.090 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 561 | 0.090 |
Why?
| | Capillaries | 2 | 2009 | 114 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 849 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 675 | 0.090 |
Why?
| | Genetic Testing | 1 | 2013 | 451 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2025 | 980 | 0.080 |
Why?
| | Night Care | 1 | 2010 | 4 | 0.080 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2011 | 85 | 0.080 |
Why?
| | Research Design | 2 | 2011 | 1118 | 0.080 |
Why?
| | After-Hours Care | 1 | 2010 | 17 | 0.080 |
Why?
| | Nervous System Diseases | 1 | 2013 | 273 | 0.080 |
Why?
| | Collagen | 1 | 2012 | 459 | 0.080 |
Why?
| | ROC Curve | 2 | 2017 | 562 | 0.080 |
Why?
| | Awards and Prizes | 1 | 2011 | 72 | 0.080 |
Why?
| | Autoantibodies | 1 | 2017 | 1456 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2015 | 1992 | 0.080 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 96 | 0.080 |
Why?
| | Colorado | 5 | 2024 | 4555 | 0.080 |
Why?
| | Organizational Culture | 1 | 2011 | 159 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 758 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1567 | 0.080 |
Why?
| | Peer Group | 1 | 2011 | 243 | 0.080 |
Why?
| | Mice | 7 | 2022 | 17814 | 0.070 |
Why?
| | Program Development | 1 | 2011 | 361 | 0.070 |
Why?
| | Gastroesophageal Reflux | 1 | 2011 | 242 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 8 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2022 | 412 | 0.070 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2008 | 7 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5798 | 0.070 |
Why?
| | Hypertension, Pulmonary | 2 | 2011 | 1924 | 0.070 |
Why?
| | Computers | 1 | 2008 | 69 | 0.070 |
Why?
| | Focus Groups | 1 | 2011 | 539 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 116 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2011 | 314 | 0.070 |
Why?
| | Half-Life | 1 | 2008 | 146 | 0.070 |
Why?
| | Chest Pain | 1 | 2008 | 96 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2010 | 331 | 0.070 |
Why?
| | Burn Units | 2 | 2022 | 48 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 2049 | 0.070 |
Why?
| | Schools | 1 | 2011 | 447 | 0.070 |
Why?
| | Radiopharmaceuticals | 1 | 2008 | 185 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 151 | 0.070 |
Why?
| | Multicenter Studies as Topic | 2 | 2022 | 320 | 0.070 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 28 | 0.070 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 433 | 0.070 |
Why?
| | Sex Factors | 1 | 2013 | 2044 | 0.070 |
Why?
| | Cell Separation | 3 | 2016 | 317 | 0.070 |
Why?
| | Indicators and Reagents | 1 | 2007 | 110 | 0.070 |
Why?
| | Georgia | 2 | 2004 | 85 | 0.070 |
Why?
| | Patient Readmission | 3 | 2019 | 703 | 0.070 |
Why?
| | Respiration Disorders | 1 | 2007 | 78 | 0.070 |
Why?
| | Cocaine-Related Disorders | 1 | 2008 | 135 | 0.060 |
Why?
| | NIH 3T3 Cells | 1 | 2007 | 148 | 0.060 |
Why?
| | Body Fluids | 1 | 2007 | 70 | 0.060 |
Why?
| | Pulmonary Artery | 2 | 2013 | 1109 | 0.060 |
Why?
| | Program Evaluation | 1 | 2011 | 916 | 0.060 |
Why?
| | Thrombocytopenia | 2 | 2019 | 206 | 0.060 |
Why?
| | Stem Cell Transplantation | 1 | 2008 | 184 | 0.060 |
Why?
| | Nursing Staff, Hospital | 1 | 2009 | 157 | 0.060 |
Why?
| | Matrix Metalloproteinases | 1 | 2007 | 95 | 0.060 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5520 | 0.060 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 651 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 316 | 0.060 |
Why?
| | Pneumonia, Bacterial | 1 | 2006 | 114 | 0.060 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1986 | 0.050 |
Why?
| | Louisiana | 1 | 2024 | 26 | 0.050 |
Why?
| | Adolescent | 6 | 2022 | 21564 | 0.050 |
Why?
| | Observation | 1 | 2004 | 56 | 0.050 |
Why?
| | Respiration | 1 | 2025 | 207 | 0.050 |
Why?
| | Hemorrhage | 2 | 2019 | 747 | 0.050 |
Why?
| | Fatty Acids, Volatile | 1 | 2024 | 58 | 0.050 |
Why?
| | Dimercaprol | 1 | 2023 | 6 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2681 | 0.050 |
Why?
| | Hand Strength | 1 | 2024 | 131 | 0.050 |
Why?
| | Hydroxyethyl Starch Derivatives | 1 | 2003 | 9 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 102 | 0.050 |
Why?
| | Time Factors | 4 | 2018 | 6851 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1415 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5803 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 35 | 0.050 |
Why?
| | Nutritional Status | 1 | 2005 | 352 | 0.050 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2022 | 21 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 72 | 0.050 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2022 | 56 | 0.050 |
Why?
| | rhoA GTP-Binding Protein | 2 | 2014 | 87 | 0.050 |
Why?
| | Vasopressins | 1 | 2022 | 60 | 0.050 |
Why?
| | North America | 1 | 2022 | 304 | 0.050 |
Why?
| | Receptors, Polymeric Immunoglobulin | 1 | 2021 | 2 | 0.040 |
Why?
| | rho-Associated Kinases | 2 | 2014 | 84 | 0.040 |
Why?
| | Transcytosis | 1 | 2021 | 7 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 321 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 133 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 192 | 0.040 |
Why?
| | Blood Alcohol Content | 1 | 2021 | 5 | 0.040 |
Why?
| | Naltrexone | 1 | 2022 | 102 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 199 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2021 | 3028 | 0.040 |
Why?
| | Bleomycin | 1 | 2022 | 247 | 0.040 |
Why?
| | Cilia | 1 | 2022 | 172 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 665 | 0.040 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2009 | 850 | 0.040 |
Why?
| | Containment of Biohazards | 1 | 2020 | 21 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1352 | 0.040 |
Why?
| | Rats | 2 | 2017 | 5594 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2020 | 59 | 0.040 |
Why?
| | Protein Transport | 1 | 2021 | 444 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 304 | 0.040 |
Why?
| | Prognosis | 3 | 2013 | 3984 | 0.040 |
Why?
| | Incidence | 2 | 2003 | 2747 | 0.040 |
Why?
| | Pharmacoepidemiology | 1 | 2019 | 20 | 0.040 |
Why?
| | Chronic Disease | 3 | 2015 | 1805 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 156 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 310 | 0.040 |
Why?
| | Qualitative Research | 1 | 2025 | 1455 | 0.030 |
Why?
| | Coronary Circulation | 1 | 2018 | 136 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 44 | 0.030 |
Why?
| | Leadership | 1 | 2022 | 390 | 0.030 |
Why?
| | Illinois | 1 | 2017 | 44 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 45 | 0.030 |
Why?
| | RNA Transport | 1 | 2017 | 23 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 156 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 137 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2022 | 673 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 98 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 788 | 0.030 |
Why?
| | Algorithms | 1 | 2024 | 1740 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 704 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2844 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 1374 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 190 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 329 | 0.030 |
Why?
| | Dried Blood Spot Testing | 1 | 2017 | 121 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 377 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2008 | 2722 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 155 | 0.030 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2016 | 34 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 12 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 316 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2017 | 247 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 147 | 0.030 |
Why?
| | Risk | 1 | 2018 | 893 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 448 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 433 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 195 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 502 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 852 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 553 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 958 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 241 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1179 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 214 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 819 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2030 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 896 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 204 | 0.030 |
Why?
| | Mental Competency | 1 | 2013 | 25 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1044 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 8 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2014 | 328 | 0.030 |
Why?
| | Ventilator Weaning | 1 | 2013 | 37 | 0.020 |
Why?
| | Survival Analysis | 1 | 2016 | 1309 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor D | 1 | 2012 | 13 | 0.020 |
Why?
| | Phylogeny | 1 | 2017 | 998 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2012 | 17 | 0.020 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 27 | 0.020 |
Why?
| | Thymus Gland | 1 | 2014 | 314 | 0.020 |
Why?
| | Biological Transport | 1 | 2014 | 403 | 0.020 |
Why?
| | Tidal Volume | 1 | 2013 | 102 | 0.020 |
Why?
| | Fibrosis | 1 | 2015 | 539 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2013 | 137 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2012 | 131 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2015 | 734 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 469 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 522 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 350 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 659 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2225 | 0.020 |
Why?
| | Bronchiolitis Obliterans | 1 | 2011 | 65 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2499 | 0.020 |
Why?
| | Microbial Viability | 1 | 2011 | 91 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 411 | 0.020 |
Why?
| | Research Personnel | 1 | 2012 | 182 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 541 | 0.020 |
Why?
| | World Health Organization | 1 | 2011 | 125 | 0.020 |
Why?
| | Proteomics | 1 | 2017 | 1110 | 0.020 |
Why?
| | Superoxides | 1 | 2011 | 217 | 0.020 |
Why?
| | Immunomodulation | 1 | 2011 | 99 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 841 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 280 | 0.020 |
Why?
| | Blood Pressure | 1 | 2017 | 1739 | 0.020 |
Why?
| | Species Specificity | 1 | 2011 | 581 | 0.020 |
Why?
| | rho GTP-Binding Proteins | 1 | 2010 | 60 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 454 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2012 | 544 | 0.020 |
Why?
| | Receptor, ErbB-2 | 1 | 2012 | 346 | 0.020 |
Why?
| | Metabolomics | 1 | 2015 | 689 | 0.020 |
Why?
| | Amides | 1 | 2010 | 97 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 375 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 50 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1760 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1746 | 0.020 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2011 | 230 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1072 | 0.020 |
Why?
| | Viruses | 1 | 2011 | 161 | 0.020 |
Why?
| | Physician-Nurse Relations | 1 | 2009 | 18 | 0.020 |
Why?
| | Leisure Activities | 1 | 2009 | 30 | 0.020 |
Why?
| | AC133 Antigen | 1 | 2008 | 20 | 0.020 |
Why?
| | Cell Fusion | 1 | 2008 | 50 | 0.020 |
Why?
| | Giant Cells | 1 | 2008 | 23 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2008 | 42 | 0.020 |
Why?
| | Mitochondria | 1 | 2015 | 955 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2008 | 90 | 0.020 |
Why?
| | Thyroxine | 1 | 2008 | 64 | 0.020 |
Why?
| | Nurse Administrators | 1 | 2009 | 44 | 0.020 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2009 | 82 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 768 | 0.020 |
Why?
| | Osteocytes | 1 | 2008 | 30 | 0.020 |
Why?
| | Breath Tests | 1 | 2007 | 76 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 265 | 0.020 |
Why?
| | Curriculum | 1 | 2014 | 1009 | 0.020 |
Why?
| | Databases as Topic | 1 | 2007 | 69 | 0.020 |
Why?
| | Child | 2 | 2022 | 21921 | 0.020 |
Why?
| | Laparoscopy | 1 | 2011 | 454 | 0.020 |
Why?
| | Social Environment | 1 | 2009 | 295 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 504 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 969 | 0.020 |
Why?
| | Job Satisfaction | 1 | 2009 | 218 | 0.020 |
Why?
| | Glycoproteins | 1 | 2008 | 354 | 0.020 |
Why?
| | Models, Biological | 1 | 2014 | 1806 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 553 | 0.020 |
Why?
| | Trauma Centers | 1 | 2009 | 428 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 331 | 0.020 |
Why?
| | Adipocytes | 1 | 2008 | 227 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1518 | 0.020 |
Why?
| | Cell Lineage | 1 | 2008 | 350 | 0.020 |
Why?
| | Antigens, CD | 1 | 2008 | 536 | 0.010 |
Why?
| | Chondrocytes | 1 | 2008 | 226 | 0.010 |
Why?
| | Telomerase | 1 | 2008 | 246 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1482 | 0.010 |
Why?
| | Health Care Costs | 1 | 2007 | 418 | 0.010 |
Why?
| | France | 1 | 2003 | 37 | 0.010 |
Why?
| | Contraindications | 1 | 2003 | 85 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 976 | 0.010 |
Why?
| | Washington | 1 | 2003 | 157 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 177 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2480 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2003 | 1317 | 0.010 |
Why?
|
|
Burnham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|